Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 12/20 | 0.57 |
| ▸ | TACR3 | P29371 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12809390 | 0.89 | TACR1 (0.65) | TACR1TACR3MITFCA1CA2 | |
| SCHEMBL14217214 | 0.84 | TACR1 (0.61) | TACR1TACR3MITF | |
| SCHEMBL13756721 | 0.84 | TACR1 (0.62) | TACR1TACR3MITFCA1CA2 | |
| SCHEMBL14217426 | 0.84 | TACR1 (0.54) | TACR1TACR3 | |
| SCHEMBL14098402 | 0.83 | TACR1 (0.67) | TACR1TACR3MITFCA1CA2 | |
| SCHEMBL4819217 | 0.82 | TACR1 (0.68) | TACR1TACR3MITFCA1CA2 | |
| SCHEMBL4819222 | 0.82 | TACR1 (0.68) | TACR1TACR3MITFCA1CA2 | |
| SCHEMBL14017628 | 0.82 | TACR1 (0.68) | TACR1TACR3MITFCA1CA2 | |
| SCHEMBL14217021 | 0.82 | TACR1 (0.61) | TACR1TACR3MITF | |
| SCHEMBL14422717 | 0.81 | TACR1 (0.74) | TACR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737838-B1 | SUBSTITUTED 4-ALKYL- AND 4-ALKANOYL-PIPERIDINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-21 | — | — | EP | disclosed |
| US-20070213346-A1 | Substituted 4-Alkyl-And 4-Alkanoyl-Piperidine Derivatives And Their Use As Neurokinin Antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-13 | — | — | US | disclosed |
| US-20070213346-A1 | Substituted 4-Alkyl-And 4-Alkanoyl-Piperidine Derivatives And Their Use As Neurokinin Antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213346-A1 | Substituted 4-Alkyl-And 4-Alkanoyl-Piperidine Derivatives And Their Use As Neurokinin Antagonists | NPSR1, VIP, OPRK1 | TACR1 36/4885TACR3 214/4885MITF 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.